Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Diluted Average): 2018-2023

Historic Shares Outstanding (Diluted Average) for Catalyst Pharmaceuticals (CPRX) over the last 6 years, with Dec 2023 value amounting to $113.8 million.

  • Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) rose 8.26% to $123.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $123.4 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of $113.8 million for FY2023, which is 2.13% up from last year.
  • According to the latest figures from FY2023, Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) is $113.8 million, which was up 2.13% from $111.4 million recorded in FY2022.
  • In the past 5 years, Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $113.8 million in FY2023 and a low of $106.0 million during FY2019.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $111.4 million (2022), whereas its average is $111.0 million.
  • Data for Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 3.32% (in 2022) over the last 5 years.
  • Over the past 5 years, Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $106.0 million in 2019, then increased by 0.21% to $106.2 million in 2020, then climbed by 1.46% to $107.8 million in 2021, then increased by 3.32% to $111.4 million in 2022, then rose by 2.13% to $113.8 million in 2023.